ISTH/ANRS 0409s INTEGRATE Lassa Fever Study

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,755

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Lassa Fever
Interventions
DRUG

Favipiravir

Interventional Medicinal Product (IMP)

DRUG

Ribavirin

Control arm

DRUG

Dexamethasone

Interventional Medicinal Product (IMP)

All Listed Sponsors
collaborator

Alliance for International Medical Action

OTHER

collaborator

University of Bordeaux

OTHER

collaborator

Bernhard Nocht Institute for Tropical Medicine

OTHER_GOV

collaborator

Federal Medical Centre, Owo

INDUSTRY

collaborator

Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire

OTHER

collaborator

Fondation pour la Recherche Scientifique, Benin

UNKNOWN

collaborator

Médecins Sans Frontières, Belgium

OTHER

collaborator

Alex Ekwueme Federal University Teaching Hospital

OTHER

collaborator

Donka Hospital, Conakry

UNKNOWN

collaborator

Centre de Recherche Médicale de Lambaréné

OTHER

collaborator

University of Hamburg-Eppendorf

OTHER

collaborator

Phebe Hospital, Liberia

UNKNOWN

collaborator

University of North Carolina

OTHER

collaborator

ANRS, Emerging Infectious Diseases

OTHER_GOV

lead

Irrua Specialist Teaching Hospital

OTHER

NCT06212336 - ISTH/ANRS 0409s INTEGRATE Lassa Fever Study | Biotech Hunter | Biotech Hunter